| Protocol |
Title |
Status |
Contact |
| 103866 |
Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Stage II-IV Melanoma |
OPEN TO ACCRUAL |
 |
| 103478 |
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) |
OPEN TO ACCRUAL |
|
| 103974 |
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors |
OPEN TO ACCRUAL |
|
| 103950 |
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103985 |
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score 25 |
OPEN TO ACCRUAL |
|
| 103994 |
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck |
OPEN TO ACCRUAL |
|
| 103892 |
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy |
OPEN TO ACCRUAL |
|
| 103683 |
GOG-3076 a Phase 3 Trial in Platinum-Resistant/Refractory Ovarian Cancer |
OPEN TO ACCRUAL |
|
| 103743 |
A Phase 1b Dose Escalation Study of AV-380 in Combination with Chemotherapy or Immunotherapy in Cancer Patients with Elevated GDF-15 Levels Colorectal Cancer, NSCLC, Pancreatic Cancer |
OPEN TO ACCRUAL |
|
| 103747 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal
Carcinoma |
OPEN TO ACCRUAL |
|
| 103984 |
OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy |
OPEN TO ACCRUAL |
|
| 104019 |
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer |
OPEN TO ACCRUAL |
|
| 103792 |
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868) |
OPEN TO ACCRUAL |
|
| 103952 |
Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 103704 |
A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) |
OPEN TO ACCRUAL |
|
| 103921 |
AHOD2131 - A Randomized, Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and Stage II Classic Hodgkin Lymphoma |
OPEN TO ACCRUAL |
|
| 103945 |
A Phase 2, Randomized Study to Evaluate the Safety, Efficacy and Optimal dose of ABBV-400 in Combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (mCRC) |
OPEN TO ACCRUAL |
|
| 103849 |
Feasibility Study- ReVeal FGS 475 System for Bevonescein-Assisted Intra-Operative Visualization of Nerves in Head and Neck Surgery |
OPEN TO ACCRUAL |
|
| 103819 |
A Phase III, Single Arm Study to Evaluate the Efficacy and Safety of ONCOFID P B (paclitaxel hyaluronic acid conjugate) Administered Intravesically to Patients with BCG unresponsive Carcinoma in Situ of the Bladder with or without Ta T1 Papillary Disease |
OPEN TO ACCRUAL |
|
| 103669 |
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer |
OPEN TO ACCRUAL |
|